NCGI
SPRY icon

Next Century Growth Investors’s ARS Pharmaceuticals SPRY Stock Holding History

Next Century Growth Investors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-622,823
Closed -$10.9M – 146
2025
Q2 		$10.9M Buy
+622,823
New +$8.99M 0.84% 43

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Next Century Growth Investors's SPRY Position: Q3 2025 in Review

Next Century Growth Investors sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 622,823 shares — an estimated $10.9M sold.

Next Century Growth Investors first reported a position in SPRY in Q2 2025 and held it in 1 quarter. The position peaked at $10.9M in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Next Century Growth Investors reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Next Century Growth Investors sold 622,823 ARS Pharmaceuticals shares in Q3 2025, an estimated $10.9M.
  • Next Century Growth Investors first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Next Century Growth Investors's ARS Pharmaceuticals position peaked at $10.9M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Next Century Growth Investors's 13F filing for Q3 2025, filed 14 Nov 2025.